| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb5ab719b7240c08da75eacc45e89cc0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36 |
| filingDate |
2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4014eae64818926ce7e3f8d95fcc69ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0082e320ab840992d76c4b6d8a7e131e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c8ed4a8ada747ffa4a57ccfcbf37649
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b64c575a5ba52fa9e207dd75ee9bfe7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20383120ef7d33142bff65af6afae49c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df612fb73136c77bc6cb50caf1676732 |
| publicationDate |
2016-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2580020-C2 |
| titleOfInvention |
Method for reducing antibody heterogeneity and method for producing related antibodies |
| abstract |
FIELD: medicine. n SUBSTANCE: present invention refers to biotechnology, more specifically to recombinant production of antibodies, and is applicable for reducing antibody heterogeneity during culturing. There are producing low-heterogeneity antibodies caused by variations of the relative contents of a lysine residue on C-terminals by adding divalent zinc ions (Zn +2 ) in the concentration of 0.05-1.5 mM to a culture medium during the culturing procedure and reducing an osmotic pressure of the cell culture medium from 240 to 260 mOsm/kg. n EFFECT: invention enables producing the high-quality monoclonal antibodies as compared to a standard technology by reducing a portion of primary variants in the antibodies having the C-terminal variation of lysine that reduces the heterogeneity in antibodies. n 15 cl, 12 dwg, 12 tbl, 12 ex |
| priorityDate |
2011-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |